The Multiplicity of Infection of Recombinant Vaccinia Virus Expressing the T7 RNA Polymerase Determines the Rescue Efficiency of Vesicular Stomatitis Virus.

Front Microbiol

State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.

Published: April 2022

AI Article Synopsis

  • Vesicular stomatitis virus (VSV) is a key model for studying negative-strand RNA viruses, focusing on how they interact with host cells and their potential for vaccine development.
  • The study discovered that using a specific multiplicity of infection (MOI) of 5 for recombinant vaccinia virus (vTF-7.3) enhances VSV rescue efficiency significantly compared to a lower MOI of 1.
  • Additionally, the research highlights that purifying vTF-7.3 before transfection is crucial for achieving optimal VSV rescue, offering insights that could improve VSV reverse genetic systems in labs.

Article Abstract

Vesicular stomatitis virus (VSV) has a wide range of cell tropism, making it a prototype of studying the negative-strand RNA virus (NSRV), including virus-host interactions and vaccine development. Although VSV rescue systems have been progressively optimized throughout time, the T7-based expression system is the most commonly utilized to rescue VSV. However, it remains a significant barrier for many labs. In our study, we found that rescue VSV's efficiency is associated with the various multiplicities of infection (MOIs) of recombinant vaccinia virus expressing the T7 RNA polymerase (vTF-7.3). It works at maximum efficiency while the MOI of vTF-7.3 is 5, which is analyzed by quantitative PCR, Western blot, and flow cytometry, compared to the lowest rescue level with MOI of 1. Meanwhile, our data also suggest that purification of vTF-7.3 prior to transfection is a prerequisite for VSV rescue. Overall, our study reveals for the first time a precise correlation between vTF-7.3 and rescue efficiency, which may aid in resolving the uncertainties in the quest to build the VSV reverse genetic system.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014117PMC
http://dx.doi.org/10.3389/fmicb.2022.846426DOI Listing

Publication Analysis

Top Keywords

recombinant vaccinia
8
vaccinia virus
8
virus expressing
8
expressing rna
8
rna polymerase
8
rescue efficiency
8
vesicular stomatitis
8
stomatitis virus
8
vsv rescue
8
rescue
7

Similar Publications

Previously obtained highly immunogenic Env-VLPs ensure overcoming the natural resistance of HIV-1 surface proteins associated with their low level of incorporation and inaccessibility of conserved epitopes to induce neutralizing antibodies. We also adopted this technology to modify Env trimers of the ZM53(T/F) strain to produce Env-VLPs by recombinant vaccinia viruses (rVVs). For VLP production, rVVs expressing Env, Gag-Pol (HIV-1/SIV), and the cowpox virus hr gene, which overcomes the restriction of vaccinia virus replication in CHO cells, were used.

View Article and Find Full Text PDF

Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein.

NPJ Vaccines

December 2024

Instituto Politécnico Nacional, IPN. Av. Luis Enrique Erro s/n. Unidad Adolfo López Mateos, Mexico City, Mexico.

Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show by cryo-electron microscopy that VLPs of Mayaro virus, which contain envelope glycoproteins E1-E2 and capsid, exhibit an architecture that closely resembles native virus. In contrast to monomeric and soluble envelope 2 (E2) glycoprotein, both VLPs as well as the adenovirus and modified vaccinia virus Ankara (MVA) vaccine platforms expressing the equivalent envelope glycoproteins E1-E2, and capsid induced highly neutralising antibodies after immunisation.

View Article and Find Full Text PDF

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine.

Methods Mol Biol

December 2024

United Kingdom Health Security Agency (UKHSA), Salisbury, Wiltshire, UK.

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials.

View Article and Find Full Text PDF

Introduction: Coronaviruses and influenza viruses are significant respiratory pathogens that cause severe disease burdens and economic losses for society. Due to their diversity and evolution, vaccines typically require periodic updating to remain effective. An additional challenge is imposed by the possible coinfection of SARS-CoV-2 and influenza, which could increase disease severity.

View Article and Find Full Text PDF
Article Synopsis
  • * This study reveals that oxaliplatin enhances the effectiveness of oncolytic virotherapy by improving virus retention in targeted tumors and altering immune responses in distant tumors.
  • * The findings suggest a potential shift in treatment strategies for patients with widespread cancer, as the combination of oxaliplatin and virotherapy may enhance overall patient survival.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!